Advancing sustainable health systems
The innovative pharmaceutical industry is a key player in the co-creation of robust, resilient, and sustainable health systems – locally, nationally, and globally.
This includes developing innovative and sustainable solutions for non-communicable diseases (NCDs), infectious diseases such as HIV, malaria, and tuberculosis, neglected tropical diseases (NTDs), and rare diseases. In addition, it covers areas like digital health and pandemic preparedness.
As well as driving innovation in medicines and health products, the industry supports improved access to medicines, diagnostics, and treatments around the world. At the same time, it responds to the social, economic, and environmental factors that impact global health outcomes.
Universal Health Coverage
IFPMA works in partnership with other members of the global health community to achieve Universal Health Coverage targets and contribute to a world where no one is left behind in receiving the healthcare they need.
The innovative pharmaceutical industry supports the discovery of new vaccines and their access to prevent and control diseases, improve the health of people everywhere, and make the world a safer place.
IFPMA helps tackle NCDs by building multi-sectoral alliances and reinforcing the importance of investing in NCD prevention and care through our policy and advocacy work.
We are committed to supporting countries achieve SDG 3.3 to end epidemics of HIV/AIDS, tuberculosis, malaria, neglected tropical diseases, and other communicable diseases.
We are driving a mindset shift regarding rare diseases that pose unique challenges to patients, their families, society, healthcare professionals, and healthcare systems.
Digital health technologies impact every aspect of the value chain, from drug discovery and clinical development to product launch and support for patients, caregivers, and healthcare professionals.